Madrid, Community of Madrid SpainNIMGenetics provides advanced Genomics, Transcriptomics, Bioinformatics and cell line characterization services leveraging NGS, Single-cell and arrayCGH technologies and expertise to support Biopharma Industry, CROs and Academic Researchers. With the recent purchase of Gene Predictis SA in Switzerland, we also include molecular microbiology analyses, polygenic risk scores development, genotyping platform & possibility to design custom genotyping arrays and validated based on our DNAtek, in vitro diagnostics development and pharmacogenetics At NIMGenetics, we pride ourselves on the Speed, Competitive Pricing and Tailored R&D Services we can offer our partners. Furthermore, NIMGenetics becomes the first human genetic diagnosis company in the world to be certified as a B Corp, thus accrediting its generation of positive social and environmental impact through its activity. We integrate the most modern technologies with an internally developed pipeline for genomic analysis, applying our own bioinformatics tools, Artificial Intelligence (AI), Machine Learning (ML) and a large proprietary genetic database. In addition, NIMGenetics’ Clinical Relationships, in Leading Hospitals and Clinics, as well as our Repository of Clinical Genomics Data, makes us an especially interesting partner to support R&D projects from the Earliest Discovery and Preclinical Stages to Clinical Trials and Companion Diagnostics (CDx). NIMGenetics offers Research and Development Support Services such as: Whole-Genome and Exome Sequencing, Gene Expression (RNASeq, Single Cell and Methylation Profiling), DNA-Encoded Chemical Libraries, Genomics for Cell and Gene Therapy, Optical Genome Mapping, CRISPR Off-target Effects, Viral Vector Integration Analysis, Bioinformatics Analysis, a growing Genomics Database of under-represented populations from the Iberian Peninsula and Latin America, and tailor-made R&D Consultancy projects. We support researchers in Oncology, Rare Diseases, Regenerative Medicine, Neurodevelopmental and Neurodegenerative Diseases, Gynecology and Reproductive Medicine, GastrointestinaI, Microbiome and a wealth of other Research Areas.

Parque científico de Madrid - C/Faraday, 7 (Campus de Cantoblanco) Madrid, 28049 SpainNIMGenetics provides advanced Genomics, Transcriptomics, Bioinformatics and cell line characterization services leveraging NGS, Single-cell and arrayCGH technologies and expertise to support Biopharma Industry, CROs and Academic Researchers. With the recent purchase of Gene Predictis SA in Switzerland, we also include molecular microbiology analyses, polygenic risk scores development, genotyping platform & possibility to design custom genotyping arrays and validated based on our DNAtek, in vitro diagnostics development and pharmacogenetics At NIMGenetics, we pride ourselves on the Speed, Competitive Pricing and Tailored R&D Services we can offer our partners. Furthermore, NIMGenetics becomes the first human genetic diagnosis company in the world to be certified as a B Corp, thus accrediting its generation of positive social and environmental impact through its activity. We integrate the most modern technologies with an internally developed pipeline for genomic analysis, applying our own bioinformatics tools, Artificial Intelligence (AI), Machine Learning (ML) and a large proprietary genetic database. In addition, NIMGenetics’ Clinical Relationships, in Leading Hospitals and Clinics, as well as our Repository of Clinical Genomics Data, makes us an especially interesting partner to support R&D projects from the Earliest Discovery and Preclinical Stages to Clinical Trials and Companion Diagnostics (CDx). NIMGenetics offers Research and Development Support Services such as: Whole-Genome and Exome Sequencing, Gene Expression (RNASeq, Single Cell and Methylation Profiling), DNA-Encoded Chemical Libraries, Genomics for Cell and Gene Therapy, Optical Genome Mapping, CRISPR Off-target Effects, Viral Vector Integration Analysis, Bioinformatics Analysis, a growing Genomics Database of under-represented populations from the Iberian Peninsula and Latin America, and tailor-made R&D Consultancy projects. We support researchers in Oncology, Rare Diseases, Regenerative Medicine, Neurodevelopmental and Neurodegenerative Diseases, Gynecology and Reproductive Medicine, GastrointestinaI, Microbiome and a wealth of other Research Areas.

c/ Faraday 7 Madrid, Madrid, 28049 SpainNIMGenetics provides advanced Genomics, Transcriptomics, Bioinformatics and cell line characterization services leveraging NGS, Single-cell and arrayCGH technologies and expertise to support Biopharma Industry, CROs and Academic Researchers. With the recent purchase of Gene Predictis SA in Switzerland, we also include molecular microbiology analyses, polygenic risk scores development, genotyping platform & possibility to design custom genotyping arrays and validated based on our DNAtek, in vitro diagnostics development and pharmacogenetics At NIMGenetics, we pride ourselves on the Speed, Competitive Pricing and Tailored R&D Services we can offer our partners. Furthermore, NIMGenetics becomes the first human genetic diagnosis company in the world to be certified as a B Corp, thus accrediting its generation of positive social and environmental impact through its activity. We integrate the most modern technologies with an internally developed pipeline for genomic analysis, applying our own bioinformatics tools, Artificial Intelligence (AI), Machine Learning (ML) and a large proprietary genetic database. In addition, NIMGenetics’ Clinical Relationships, in Leading Hospitals and Clinics, as well as our Repository of Clinical Genomics Data, makes us an especially interesting partner to support R&D projects from the Earliest Discovery and Preclinical Stages to Clinical Trials and Companion Diagnostics (CDx). NIMGenetics offers Research and Development Support Services such as: Whole-Genome and Exome Sequencing, Gene Expression (RNASeq, Single Cell and Methylation Profiling), DNA-Encoded Chemical Libraries, Genomics for Cell and Gene Therapy, Optical Genome Mapping, CRISPR Off-target Effects, Viral Vector Integration Analysis, Bioinformatics Analysis, a growing Genomics Database of under-represented populations from the Iberian Peninsula and Latin America, and tailor-made R&D Consultancy projects. We support researchers in Oncology, Rare Diseases, Regenerative Medicine, Neurodevelopmental and Neurodegenerative Diseases, Gynecology and Reproductive Medicine, GastrointestinaI, Microbiome and a wealth of other Research Areas.

Calle Anabel Segura 16 Edificio Vega Norte - Ed. 3 1ª planta Alcobendas, Madrid, 28108 SpainNIMGenetics provides advanced Genomics, Transcriptomics, Bioinformatics and cell line characterization services leveraging NGS, Single-cell and arrayCGH technologies and expertise to support Biopharma Industry, CROs and Academic Researchers. With the recent purchase of Gene Predictis SA in Switzerland, we also include molecular microbiology analyses, polygenic risk scores development, genotyping platform & possibility to design custom genotyping arrays and validated based on our DNAtek, in vitro diagnostics development and pharmacogenetics At NIMGenetics, we pride ourselves on the Speed, Competitive Pricing and Tailored R&D Services we can offer our partners. Furthermore, NIMGenetics becomes the first human genetic diagnosis company in the world to be certified as a B Corp, thus accrediting its generation of positive social and environmental impact through its activity. We integrate the most modern technologies with an internally developed pipeline for genomic analysis, applying our own bioinformatics tools, Artificial Intelligence (AI), Machine Learning (ML) and a large proprietary genetic database. In addition, NIMGenetics’ Clinical Relationships, in Leading Hospitals and Clinics, as well as our Repository of Clinical Genomics Data, makes us an especially interesting partner to support R&D projects from the Earliest Discovery and Preclinical Stages to Clinical Trials and Companion Diagnostics (CDx). NIMGenetics offers Research and Development Support Services such as: Whole-Genome and Exome Sequencing, Gene Expression (RNASeq, Single Cell and Methylation Profiling), DNA-Encoded Chemical Libraries, Genomics for Cell and Gene Therapy, Optical Genome Mapping, CRISPR Off-target Effects, Viral Vector Integration Analysis, Bioinformatics Analysis, a growing Genomics Database of under-represented populations from the Iberian Peninsula and Latin America, and tailor-made R&D Consultancy projects. We support researchers in Oncology, Rare Diseases, Regenerative Medicine, Neurodevelopmental and Neurodegenerative Diseases, Gynecology and Reproductive Medicine, GastrointestinaI, Microbiome and a wealth of other Research Areas.

Calle Faraday 7 Parque Científico de Madrid Madrid, Madrid, 28049 SpainNIMGenetics provides advanced Genomics, Transcriptomics, Bioinformatics and cell line characterization services leveraging NGS, Single-cell and arrayCGH technologies and expertise to support Biopharma Industry, CROs and Academic Researchers. With the recent purchase of Gene Predictis SA in Switzerland, we also include molecular microbiology analyses, polygenic risk scores development, genotyping platform & possibility to design custom genotyping arrays and validated based on our DNAtek, in vitro diagnostics development and pharmacogenetics At NIMGenetics, we pride ourselves on the Speed, Competitive Pricing and Tailored R&D Services we can offer our partners. Furthermore, NIMGenetics becomes the first human genetic diagnosis company in the world to be certified as a B Corp, thus accrediting its generation of positive social and environmental impact through its activity. We integrate the most modern technologies with an internally developed pipeline for genomic analysis, applying our own bioinformatics tools, Artificial Intelligence (AI), Machine Learning (ML) and a large proprietary genetic database. In addition, NIMGenetics’ Clinical Relationships, in Leading Hospitals and Clinics, as well as our Repository of Clinical Genomics Data, makes us an especially interesting partner to support R&D projects from the Earliest Discovery and Preclinical Stages to Clinical Trials and Companion Diagnostics (CDx). NIMGenetics offers Research and Development Support Services such as: Whole-Genome and Exome Sequencing, Gene Expression (RNASeq, Single Cell and Methylation Profiling), DNA-Encoded Chemical Libraries, Genomics for Cell and Gene Therapy, Optical Genome Mapping, CRISPR Off-target Effects, Viral Vector Integration Analysis, Bioinformatics Analysis, a growing Genomics Database of under-represented populations from the Iberian Peninsula and Latin America, and tailor-made R&D Consultancy projects. We support researchers in Oncology, Rare Diseases, Regenerative Medicine, Neurodevelopmental and Neurodegenerative Diseases, Gynecology and Reproductive Medicine, GastrointestinaI, Microbiome and a wealth of other Research Areas.

Rua Elvira Ferraz nº 250 Cj. 211 Itaim, São Paulo SP, 04552-040 BrazilNIMGenetics provides advanced Genomics, Transcriptomics, Bioinformatics and cell line characterization services leveraging NGS, Single-cell and arrayCGH technologies and expertise to support Biopharma Industry, CROs and Academic Researchers. With the recent purchase of Gene Predictis SA in Switzerland, we also include molecular microbiology analyses, polygenic risk scores development, genotyping platform & possibility to design custom genotyping arrays and validated based on our DNAtek, in vitro diagnostics development and pharmacogenetics At NIMGenetics, we pride ourselves on the Speed, Competitive Pricing and Tailored R&D Services we can offer our partners. Furthermore, NIMGenetics becomes the first human genetic diagnosis company in the world to be certified as a B Corp, thus accrediting its generation of positive social and environmental impact through its activity. We integrate the most modern technologies with an internally developed pipeline for genomic analysis, applying our own bioinformatics tools, Artificial Intelligence (AI), Machine Learning (ML) and a large proprietary genetic database. In addition, NIMGenetics’ Clinical Relationships, in Leading Hospitals and Clinics, as well as our Repository of Clinical Genomics Data, makes us an especially interesting partner to support R&D projects from the Earliest Discovery and Preclinical Stages to Clinical Trials and Companion Diagnostics (CDx). NIMGenetics offers Research and Development Support Services such as: Whole-Genome and Exome Sequencing, Gene Expression (RNASeq, Single Cell and Methylation Profiling), DNA-Encoded Chemical Libraries, Genomics for Cell and Gene Therapy, Optical Genome Mapping, CRISPR Off-target Effects, Viral Vector Integration Analysis, Bioinformatics Analysis, a growing Genomics Database of under-represented populations from the Iberian Peninsula and Latin America, and tailor-made R&D Consultancy projects. We support researchers in Oncology, Rare Diseases, Regenerative Medicine, Neurodevelopmental and Neurodegenerative Diseases, Gynecology and Reproductive Medicine, GastrointestinaI, Microbiome and a wealth of other Research Areas.

Avenida Prof. Gama Pinto nº 2 Complexo Interdisciplinar da Universidade de Lisboa, Salas 2.12 – 2.14 Lisboa, Lisboa, 1649-003 PortugalNIMGenetics provides advanced Genomics, Transcriptomics, Bioinformatics and cell line characterization services leveraging NGS, Single-cell and arrayCGH technologies and expertise to support Biopharma Industry, CROs and Academic Researchers. With the recent purchase of Gene Predictis SA in Switzerland, we also include molecular microbiology analyses, polygenic risk scores development, genotyping platform & possibility to design custom genotyping arrays and validated based on our DNAtek, in vitro diagnostics development and pharmacogenetics At NIMGenetics, we pride ourselves on the Speed, Competitive Pricing and Tailored R&D Services we can offer our partners. Furthermore, NIMGenetics becomes the first human genetic diagnosis company in the world to be certified as a B Corp, thus accrediting its generation of positive social and environmental impact through its activity. We integrate the most modern technologies with an internally developed pipeline for genomic analysis, applying our own bioinformatics tools, Artificial Intelligence (AI), Machine Learning (ML) and a large proprietary genetic database. In addition, NIMGenetics’ Clinical Relationships, in Leading Hospitals and Clinics, as well as our Repository of Clinical Genomics Data, makes us an especially interesting partner to support R&D projects from the Earliest Discovery and Preclinical Stages to Clinical Trials and Companion Diagnostics (CDx). NIMGenetics offers Research and Development Support Services such as: Whole-Genome and Exome Sequencing, Gene Expression (RNASeq, Single Cell and Methylation Profiling), DNA-Encoded Chemical Libraries, Genomics for Cell and Gene Therapy, Optical Genome Mapping, CRISPR Off-target Effects, Viral Vector Integration Analysis, Bioinformatics Analysis, a growing Genomics Database of under-represented populations from the Iberian Peninsula and Latin America, and tailor-made R&D Consultancy projects. We support researchers in Oncology, Rare Diseases, Regenerative Medicine, Neurodevelopmental and Neurodegenerative Diseases, Gynecology and Reproductive Medicine, GastrointestinaI, Microbiome and a wealth of other Research Areas.

EPFL Innovation Park building B Lausanne, Lausanne, 1015 SwitzerlandNIMGenetics provides advanced Genomics, Transcriptomics, Bioinformatics and cell line characterization services leveraging NGS, Single-cell and arrayCGH technologies and expertise to support Biopharma Industry, CROs and Academic Researchers. With the recent purchase of Gene Predictis SA in Switzerland, we also include molecular microbiology analyses, polygenic risk scores development, genotyping platform & possibility to design custom genotyping arrays and validated based on our DNAtek, in vitro diagnostics development and pharmacogenetics At NIMGenetics, we pride ourselves on the Speed, Competitive Pricing and Tailored R&D Services we can offer our partners. Furthermore, NIMGenetics becomes the first human genetic diagnosis company in the world to be certified as a B Corp, thus accrediting its generation of positive social and environmental impact through its activity. We integrate the most modern technologies with an internally developed pipeline for genomic analysis, applying our own bioinformatics tools, Artificial Intelligence (AI), Machine Learning (ML) and a large proprietary genetic database. In addition, NIMGenetics’ Clinical Relationships, in Leading Hospitals and Clinics, as well as our Repository of Clinical Genomics Data, makes us an especially interesting partner to support R&D projects from the Earliest Discovery and Preclinical Stages to Clinical Trials and Companion Diagnostics (CDx). NIMGenetics offers Research and Development Support Services such as: Whole-Genome and Exome Sequencing, Gene Expression (RNASeq, Single Cell and Methylation Profiling), DNA-Encoded Chemical Libraries, Genomics for Cell and Gene Therapy, Optical Genome Mapping, CRISPR Off-target Effects, Viral Vector Integration Analysis, Bioinformatics Analysis, a growing Genomics Database of under-represented populations from the Iberian Peninsula and Latin America, and tailor-made R&D Consultancy projects. We support researchers in Oncology, Rare Diseases, Regenerative Medicine, Neurodevelopmental and Neurodegenerative Diseases, Gynecology and Reproductive Medicine, GastrointestinaI, Microbiome and a wealth of other Research Areas.

Avenida Isla Graciosa 3 San Sebastian del los Reyes, Madrid, 28703 SpainNIMGenetics provides advanced Genomics, Transcriptomics, Bioinformatics and cell line characterization services leveraging NGS, Single-cell and arrayCGH technologies and expertise to support Biopharma Industry, CROs and Academic Researchers. With the recent purchase of Gene Predictis SA in Switzerland, we also include molecular microbiology analyses, polygenic risk scores development, genotyping platform & possibility to design custom genotyping arrays and validated based on our DNAtek, in vitro diagnostics development and pharmacogenetics At NIMGenetics, we pride ourselves on the Speed, Competitive Pricing and Tailored R&D Services we can offer our partners. Furthermore, NIMGenetics becomes the first human genetic diagnosis company in the world to be certified as a B Corp, thus accrediting its generation of positive social and environmental impact through its activity. We integrate the most modern technologies with an internally developed pipeline for genomic analysis, applying our own bioinformatics tools, Artificial Intelligence (AI), Machine Learning (ML) and a large proprietary genetic database. In addition, NIMGenetics’ Clinical Relationships, in Leading Hospitals and Clinics, as well as our Repository of Clinical Genomics Data, makes us an especially interesting partner to support R&D projects from the Earliest Discovery and Preclinical Stages to Clinical Trials and Companion Diagnostics (CDx). NIMGenetics offers Research and Development Support Services such as: Whole-Genome and Exome Sequencing, Gene Expression (RNASeq, Single Cell and Methylation Profiling), DNA-Encoded Chemical Libraries, Genomics for Cell and Gene Therapy, Optical Genome Mapping, CRISPR Off-target Effects, Viral Vector Integration Analysis, Bioinformatics Analysis, a growing Genomics Database of under-represented populations from the Iberian Peninsula and Latin America, and tailor-made R&D Consultancy projects. We support researchers in Oncology, Rare Diseases, Regenerative Medicine, Neurodevelopmental and Neurodegenerative Diseases, Gynecology and Reproductive Medicine, GastrointestinaI, Microbiome and a wealth of other Research Areas.